Amicus Therapeutics Inc Presents Positive Interim Clinical Data for CLN6 Batten Disease Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Amicus conference call to discuss interim clinical data in CLN6 Batten disease. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Vice President of Investor Relations and Corporate Communications, Ms. Sara Pellegrino. You may begin.
Good morning. Thank you for joining our conference call to discuss the positive interim clinical data for the Amicus AAV gene therapy and CLN6 Batten disease. Speaking on today's call from Amicus, we have John Crowley, Chairman and Chief Executive Officer; Dr. Jay Barth, Chief Medical Officer; and Dr. Jill Weimer, Senior Vice President of Discovery, Research and Gene Therapy Science. Also joining from the Q&A are Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; Dr. Hung Do, Chief Science Officer; and Dr. Jeff Castelli, Chief Portfolio Officer and Head of Gene
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |